Mealey's (April 10, 2020, 1:33 PM EDT) -- BOSTON — A federal district court did not err in dismissing federal securities law claims brought against a biopharmaceutical company and certain of its executive officers for allegedly misrepresenting the likelihood...
Court Correct In Dismissing Investor Claims Due To Lack Of Scienter, Panel Rules
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login